Senti Biosciences (SNTI) News Today $2.25 -0.07 (-3.02%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 20, 2024 | bizjournals.comTech icon leads $125 million push to develop cancer immunotherapiesJuly 16, 2024 | globenewswire.comSenti Bio Announces Reverse Stock SplitJuly 2, 2024 | marketbeat.comComplete Solaria, Senti, and POET: 3 High Volume Penny StocksHigh volume can indicate market strength, but volume is relative. Thirty million in traded shares doesn't mean much if the average daily volume is higher.July 2, 2024 | marketbeat.comComplete Solaria, Senti, and POET: 3 High Volume Penny Stocks (SNTI)Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices.July 1, 2024 | globenewswire.comSenti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell TherapyJune 25, 2024 | investorplace.comWhy Is Senti Biosciences (SNTI) Stock Up 32% Today?May 13, 2024 | finance.yahoo.comSenti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaMay 10, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsMay 10, 2024 | msn.comSenti Biosciences GAAP EPS of -$0.26May 10, 2024 | investorplace.comSNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024May 9, 2024 | globenewswire.comSenti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsApril 30, 2024 | globenewswire.comSenti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)March 23, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsMarch 21, 2024 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsFebruary 4, 2024 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), Guidance and ForecastJanuary 8, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramJanuary 5, 2024 | marketwatch.comSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer TreatmentJanuary 5, 2024 | finance.yahoo.comSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramDecember 22, 2023 | finance.yahoo.comWhy Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?December 22, 2023 | markets.businessinsider.comSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic MalignanciesDecember 22, 2023 | finance.yahoo.comSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNovember 24, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 13, 2023 | finance.yahoo.comSenti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 11, 2023 | morningstar.comSenti Biosciences Inc SNTINovember 7, 2023 | msn.comWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?November 7, 2023 | msn.comWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?November 7, 2023 | msn.comWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?November 6, 2023 | finance.yahoo.comSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaOctober 31, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingOctober 9, 2023 | bizjournals.comGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facilitySeptember 27, 2023 | investing.comShanti Overseas India Ltd (SNTI)September 27, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingSeptember 26, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming ConferencesAugust 15, 2023 | msn.comChardan Capital Reiterates Senti Biosciences (SNTI) Buy RecommendationAugust 11, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue EstimatesAugust 10, 2023 | finance.yahoo.comSenti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon PartnersJune 5, 2023 | finance.yahoo.comHere's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash WiselyMay 11, 2023 | msn.comChardan Capital Maintains Senti Biosciences (SNTI) Buy RecommendationMay 9, 2023 | finance.yahoo.comSenti Bio Announces First Quarter 2023 Results and Pipeline UpdatesMay 2, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual MeetingApril 17, 2023 | finance.yahoo.comSenti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR MeetingApril 14, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming Investor ConferencesMarch 24, 2023 | markets.businessinsider.comExpert Ratings for Senti BiosciencesMarch 24, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)March 24, 2023 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), DividendsMarch 23, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 22, 2023 | finance.yahoo.comSenti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 14, 2023 | finance.yahoo.comSenti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of cash before the Fed's next meeting (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview SNTI Media Mentions By Week SNTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNTI News Sentiment▼0.520.62▲Average Medical News Sentiment SNTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNTI Articles This Week▼30▲SNTI Articles Average Week Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aligos Therapeutics News Dyadic International News IN8bio News Curis News Achilles Therapeutics News Cyclo Therapeutics News Quince Therapeutics News MiNK Therapeutics News Pluri News NKGen Biotech News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNTI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
